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Glucagon-like peptide-1 (GLP-1), an insulinotropic
gut peptide released after eating, is essential for
normal glucose tolerance (GT). To determinewhether
this effect is mediated directly by GLP-1 receptors
(GLP1R) on islet b cells, we developed mice with b
cell-specific knockdown ofGlp1r. b cellGlp1r knock-
downmice had impairedGT after intraperitoneal (i.p.)
glucose and did not secrete insulin in response to i.p.
or intravenous GLP-1. However, they had normal GT
after oral glucose, a response that was impaired by a
GLP1R antagonist. b cell Glp1r knockdown mice
had blunted responses to a GLP1R agonist but
intact glucose lowering with a dipeptidylpeptidase
4 (DPP-4) inhibitor. Thus, in mice, b cell Glp1rs are
required to respond to hyperglycemia and exoge-
nous GLP-1, but other factors compensate for
reduced GLP-1 action during meals. These results
support a role for extraislet GLP1R in oral glucose
tolerance and paracrine regulation of b cells by islet
GLP-1.
INTRODUCTION
Glucagon-like peptide-1 (GLP-1), a peptide produced by
mucosal endocrine cells in the distal intestine, is released from
the gut into the circulation after nutrient ingestion. GLP-1 is
generally thought to signal as a hormone, directly activating b
cell GLP-1 receptor (GLP1R) to enhance glucose-stimulated in-
sulin secretion, i.e., the incretin effect (Campbell and Drucker,
2013; Kieffer and Habener, 1999). In addition, GLP-1 has a broad
range of actions that contribute to glucose regulation, including
inhibition of glucagon secretion and gastrointestinal motility,
suppression of hepatic glucose production, and reduction of
appetite (Barrera et al., 2011a; Campbell and Drucker, 2013).
Based on these physiologic actions, the GLP1R is a logical phar-
macologic target, and there are now two classes of drugs for1050 Cell Metabolism 19, 1050–1057, June 3, 2014 ª2014 Elsevier Intype 2 diabetes, GLP1R agonists and inhibitors of dipeptidylpep-
tidase 4 (DPP-4i), that act through this receptor (Drucker and
Nauck, 2006).
There are several reasons to question the conventional endo-
crine model proposed for GLP-1 action, a view recently ex-
pressed by several groups (D’Alessio, 2011; Holst and Deacon,
2005). First, GLP-1 circulates in relatively low concentrations
and postprandial changes in plasma levels are modest
compared to other gut hormones (Baggio and Drucker, 2007;
Vilsbøll et al., 2003). Second, GLP-1 is rapidly inactivated by
dipeptidylpeptidase 4, resulting in a very short plasma half-life
limiting availability to target cells (Deacon et al., 1995). It has
been estimated that 90% of secreted GLP-1 is metabolized
by DPP-4 before reaching the central venous circulation (Hansen
et al., 1999; Holst and Deacon, 2005). Finally, there is growing
evidence that GLP-1 regulates glucose metabolism indirectly
via GLP1R expressed on peripheral and central neurons (Donath
and Burcelin, 2013; Vahl et al., 2007; Waget et al., 2011). This
study was designed to determine whether GLP-1 mediates insu-
lin secretion and glucose lowering as a hormone acting directly
on islet b cells.RESULTS AND DISCUSSION
b Cell GLP1Rs Are Not Necessary for Normal Oral
Glucose Tolerance
To address the role of b cell GLP1R on glucose homeostasis, a
Cre-loxP strategy was used to create a mouse line, Glp1rf/f,
permitting tissue-specific knockdown of the Glp1r gene (Fig-
ure 1A, upper panel; Figures S1A and S1B, available online;
Supplemental Experimental Procedures). Mice with Glp1rf/f
were crossed with animals expressing Cre recombinase ubiqui-
tously under the control of a cytomegalovirus (CMV) promoter to
create CMVcre;Glp1rD/D mice (Glp1rCMVKO) that are functionally
global knockouts (Figures 1D, upper panel, and S1C). The
Glp1rf/f mice were also crossed with lines expressing Cre in the
b cell either under constitutive control with a rat insulin promoter
(RIP) or under tamoxifen-inducible regulation using a mouse
insulin promoter (MIPcreER) (Kaihara et al., 2013; Wicksteed
et al., 2010) (Figures S1D–S1F). To demonstrate b cell-specificc.
Figure 1. Description and Validation of Glp1rf/f and Cre Lines
(A) Upper panel: schematic depicting the location of loxP sites inserted within Glp1r gene and the result of exons 6 and 7 deletion. Lower panel: agarose gel
electrophoresis of PCR products from primers designed to generate amplicons spanning exons 6 and 7 in the Glp1r gene; the WT band is 522 bp and the
truncated band 211 bp.
(B) Pancreatic sections from RIPcre and MIPcreER lines crossed with a ‘‘double reporter’’ (DR) mouse constitutively expressing membrane-localized dtTomato
fluorescent protein that is replaced by enhanced GFP (EGFP) with exposure to Cre recombinase. RIPcre3 DR (A and D) and tamoxifen-treated MIPcreER3 DR
(B and E) show reduced red fluorescence under a Cy5 filter (A and B) and diffuse islet EGFP under fluorescein isothiocyanate (D and E); MIPcreER 3 DR given
vehicle retain more red fluorescence (C) and have minimal EGFP (F).
(C) Upper panel: cAMP accumulation in isolated islets (40 islets/sample, eight mice per group, four separate isolations) incubated for 15 min in media containing
IBMX with 10 nM Ex-4 or control (vehicle red; tamoxifen blue; ***p% 0.001). Lower panel: insulin concentrations in media from the islet studies described for top
panel (vehicle, red; tamoxifen, blue; *p% 0.05).
(D) Upper panel: no effect of exendin-4 or liraglutide on cumulative 4 hr food intake in Glp1r CMVKO compared with Glp1rWT mice (eight per group); lower panel:
food intake in tamoxifen- or vehicle-treated MIPcreER;Glp1r f/f mice (eight per group) in the 6 hr after administration of 2.5 mg Ex-4 i.p. or saline (***p% 0.001).
(E) Upper panel: body weight in vehicle- and tamoxifen-treated MIPcreER;Glpr1 f/f animals (78 Veh- and 95 Tam-treated mice); lower panel: fasting glucose in
vehicle- and tamoxifen-treated MIPcreER;Glpr1 f/f animals (95 Veh- and 107 Tam-treated mice; ***p% 0.001). NS, not significant; T, tamoxifen; V, vehicle.
All data presented as mean ± SEM. See also Figures S1 and S2.
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b Cell-Specific Knockdown of Glp1rdisruption of Glp1r, islets were isolated from Glp1rWT,
Glp1rCMVKO, RIPcre;Glp1r f/f, and tamoxifen- or vehicle-treated
MIPcreER;Glp1r f/f mice. RNA was extracted followed by PCR
of cDNA using primers that generated a product spanning the
deleted exons 6 and 7 (Figure 1A, upper panel). Wild-type (WT)
mice had a transcript of 522 bp that defined the intact Glp1r
gene. Islets from Glp1rCMVKO expressed exclusively a truncated
cDNA of 211 bp due to deletion of the floxed portion of theGlp1r
(Figure 1A, lower panel). MIPcreER;Glp1r f/f mice treated with
tamoxifen, and RIPcre;Glp1r f/f mice, expressed both WT and
truncated products. Islet Cre expression under the control ofCellthe CMV, RIP, andMIP promoters was comparable (Figure S1H).
Fidelity of Cre expression in both the RIPcre and MIPcreER lines
was confirmed by crossing each with a ‘‘double reporter’’
Gt(ROSA)26Sortm4 (ACTB-tdTomato,-enhanced GFP)Luo/J
line (Figure 1B). RIPcre mice (Figure 1B, subpanels A and D),
and MIPcreER mice treated with tamoxifen (Figure 1B, B
and E), demonstrated robust islet-specific recombination,
whereas MIPcreER mice treated with vehicle showed minimal
recombination (Figure 1B, C and F). In contrast to the RIPcre
construct, MIPcreER did not induce recombination in the hypo-
thalamus (Figure S1G). Isolated islets, and b cells sorted fromMetabolism 19, 1050–1057, June 3, 2014 ª2014 Elsevier Inc. 1051
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b Cell-Specific Knockdown of Glp1rislet cell digests, demonstrated 70%–80% knockdown of Glp1r
mRNA expression after tamoxifen treatment, respectively (Fig-
ures S2A–S3G). Consistent with the RNA results, isolated islets
from tamoxifen-treated mice did not increase cytosolic cyclic
AMP (cAMP) (Figure 1C, upper panel) or secrete insulin (Fig-
ure 1C, lower panel) in response to the GLP1R agonist
exendin-4. However, in contrast to in animals with a global dele-
tion of Glp1r (Figure 1D, upper panel), food intake was sup-
pressed in mice with b cell knockdown of the Glp1r in response
to GLP1R agonists (Figure 1D, lower panel), and they lost weight
with chronic liraglutide treatment (Figure S2I). b cell-specific
Glp1r knockdown did not affect body weight (vehicle [Veh]
32 ± 0.7 g and tamoxifen [Tam] 31 ± 0.5 g; Figure 1E, upper
panel) but caused a small, significant increase in fasting blood
glucose (Veh 143 ± 2 mg/dl and Tam 157 ± 2.6 mg/dl;
p < 0.001; Figure 1E, lower panel). Expression of proinsulin
and proglucagon mRNA was similar in tamoxifen- and vehicle-
treated MIPcreER;Glp1rf/f mice (Figure S2H).
The effect of b cell-specific GLP1R signaling on glucose toler-
ance (GT) was examined by comparing WT, MIPcreER;Glp1rf/f,
RIPcre;Glp1r f/f, and Glp1rCMVKO mice. Compared to Glp1rWT,
animals with a global deletion of the Glp1r had impaired oral
GT (Figure 2A). In contrast, the glycemic response to oral
glucose loading did not differ between RIPcre;Glp1rf/f and con-
trols (Figure S3A) or between tamoxifen- and vehicle-treated
MIPcreER;Glp1rf/f mice (Figure 1B), results that were repeatable
in multiple separate cohorts (Figure S3C). Moreover, in response
to oral glucose, mice with b cell Glp1r knockdown had similar in-
sulin secretion (Figure 2C), comparable postprandial GLP-1
levels, and diminished plasma glucose-dependent insulinotropic
polypeptide (GIP) (Figure 2D) compared to controls. To further
test the question of whether meal-induced GLP-1 acts directly
on b cells, glucose levels were measured in tamoxifen- and
vehicle-treated MIPcreER;Glp1rf/f mice that had been trained
to spontaneously ingest a fixed amount of mixed liquid nutrients.
Similar to the glucose tolerance tests (GTTs) with gastric gavage
of glucose, postprandial glucose excursions were almost iden-
tical in the two groups (Figure 2E). These findings demonstrate
that, during enteral glucose absorption, the setting under which
GLP-1 levels increase in the circulation, b cell GLP1Rs are not
necessary for normal glycemia.
To determine whether extraislet GLP1Rs are important for
normal oral glucose tolerance, WT mice or animals with b cell-
specific knockdown of theGlp1r had oral glucose tolerance tests
with and without the GLP1R antagonist exendin-(9-39) (Ex-9).
Blockade of the Glp1r caused glucose intolerance in both WT
mice and animals with b cell Glp1r knockdown (Figures 1F,
S3E, and S3F), implicating non-b cell GLP1R in the incretin effect
and regulation of postprandial glucose. Recent evidence sug-
gests that GLP-1 has direct effects on islet a cells (De Marinis
et al., 2010), and we cannot rule out the possibility that wors-
ening of glucose tolerance during acute GLP1R blockade is
due to interference with glucagon suppression.
b Cell GLP1Rs Are Necessary for a Normal Response
to i.p. Glucose
In contrast to the results with oral glucose, b cell Glp1r knock-
down with either RIPcre (Figure S3B) or MIPcreER (Figure 2G)
caused significant glucose intolerance in mice receiving intra-1052 Cell Metabolism 19, 1050–1057, June 3, 2014 ª2014 Elsevier Inperitoneal (i.p.) glucose; this is similar to the response in
Glp1rCMVKO animals (Figure 2H). Mice heterozygous for deletion
of the GLP-1 receptor, MIPcreER;Glp1r D/f mice (see Supple-
mental Experimental Procedures), treated with vehicle had
similar i.p. glucose tolerance to controls with a full complement
ofGlp1r (Figure 2I). MIPcreER;Glp1r D/fmice treated with tamox-
ifen, a more complete b cell-specific knockdown, had impaired
i.p. glucose tolerance. To determine whether the abnormal intra-
peritoneal glucose tolerance test (IPGTT) was due to a lack of
islet Glp1r, MIPcreER;Glp1rf/f mice had i.p. glucose tolerance
tests with and without Ex-9. Acute blockade of the Glp1r caused
glucose intolerance in vehicle-treated mice but had no effect in
animals with b cell Glp1r knockdown (Figure 2J). These results
support the importance of b cell GLP1R in the correction of i.p.
glucose-induced hyperglycemia. Consistent with these results,
tamoxifen-treated MIPcreER;Glp1rf/f mice had higher glucose
levels following intravenous (i.v.) glucose administration than
vehicle-treated controls (Figure S3D). Because glucose adminis-
tered i.p. or i.v. causes hyperglycemia but does not affect the
release of gastrointestinal hormones or the neural activation
that contribute to insulin secretion after meals (Thorens, 2011),
these results suggest that b cell GLP1Rs are needed for normal
b cell sensitivity to hyperglycemia, independent of acute
changes in circulating GLP-1.
b Cell-Specific Knockdown of Glp1r Eliminates the
Insulin Responses to i.v. and i.p. GLP-1
To analyze the role of exogenous GLP-1 on glucose tolerance in
the absence of b cell GLP1R, tamoxifen- and vehicle-treated
MIPcreER;Glp1r f/f were given i.p. or i.v. GLP-1 during an i.p.
glucose tolerance test. Vehicle-treated mice had substantial
improvement in i.p. glucose tolerance when given parenteral
GLP-1, and this was associated with a significant increase in
insulin secretion (Figures 3A–3C). In contrast, the tamoxifen-
treated animals had a modest reduction of glycemia when given
i.p. GLP-1 but no increase in plasma insulin. This muted effect on
glycemia is presumably the result of insulin-independent actions
of GLP-1. In response to i.v. GLP-1, there was no effect on
plasma glucose or insulin in tamoxifen-treated MIPcreER;
Glp1r f/f mice (Figures 3D–3F). Similar to MIPcreER;Glp1r f/f
mice, mice heterozygous for deletion of the GLP-1 receptor,
MIPcreER;Glp1r D/f, and treated with tamoxifen had no response
to i.v. GLP-1 (Figures 3G and 3F). Taken together with the results
of i.p. GLP-1 administration, the lack of an insulin response to i.v.
GLP-1 in the setting of a robust response in vehicle-treated con-
trols confirms a reduction of b cell Glp1r in tamoxifen-treated
MIPcreER Glp1r f/f mice to a degree that eliminates detectable
effects in vivo. Moreover, the differential effects of i.p. and i.v.
GLP-1, with a partial glucose response to the former but com-
plete absence of glucose lowering with the latter, suggests
that the GLP-1 system is compartmentalized, with some glucor-
egulatory GLP1R sequestered from peptide in the circulation but
available to peptide in the peritoneal cavity.
Our studies of the physiologic role of GLP1R during oral and
i.p. glucose challenges have similarities and differences to a
recent report of glucose tolerance in global Glp1r null animals
with transgenic expression of a human GLP1R construct specif-
ically in b cells (Lamont et al., 2012). Mice with islet rescue of the
GLP1R also recovered an insulinotropic response to anc.
Figure 2. Effects of Global or Selective Glp1r Disruption on Glucose Tolerance
(A) Blood glucose during OGTT in Glp1rCMVKO and Glp1rWT mice with corresponding area under the curve (AUC).
(B) Blood glucose (2.0 g/kg; 20% glucose) during OGTT in MIPcreER;Glp1rf/f mice treated with tamoxifen or vehicle (see also Figure S3C).
(C) Insulin concentrations from GTT depicted in (B) (one-tailed t test p < 0.05).
(D) GIP and total GLP-1 concentrations obtained at 15 min following an OGTT in MIPcreER;Glp1rf/f mice treated with tamoxifen or vehicle.
(E) Blood glucose following voluntarily ingested mixed liquid meal in MIPcreER;Glp1rf/f mice treated with T or V.
(F) AUC of blood glucose during OGTT in Glp1rWT/f and tamoxifen-treated MIPcreER;Glp1rf/f mice given saline or the GLP1R antagonist Ex-9 (100 mg/kg; see
Figure S3E and F for corresponding glucose curves).
(G) Blood glucose (2.0 g/kg; 20% glucose) during IPGTT in MIPcreER;Glp1rf/f mice treated with tamoxifen or vehicle.
(H) Blood glucose during IPGTT in Glp1rCMVKO and Glp1rWT mice.
(I) IPGTT inmice with a heterozygous globalGlp1r knockout (D/f: Tam), b cell-specific deletion ofGlp1r (tamoxifen-treatedMIPcreER;Glp1r D/f;D/f: Veh), and a full
complement of Glp1r (WT; Glp1 WT/f).
(J) AUC of blood glucose following IPGTT in vehicle- and tamoxifen-treated MIPcreER;Glp1rf/f mice with and without Ex-9 (vehicle, red; tamoxifen, blue).
Experiments used 7–11 mice per group; *p% 0.05; **p% 0.01; ***p% 0.001.
All data presented as mean ± SEM. See also Figure S3B for IPGTT results in RIPcre;Glp1rf/f mice.
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b Cell-Specific Knockdown of Glp1rexogenous GLP1R agonist, similar to the results described here.
However, these animals had improved oral glucose tolerance
compared to Glp1r null mice, supporting a direct effect of circu-
lating GLP-1 on b cells, a finding that is at odds with the normal
oral glucose tolerance we have observed repeatedly in mice with
b cell-specific Glp1r knockdown. This discrepancy could be
explained either by nonphysiologic expression of the humanCellGLP1R construct in the rescue model or insufficient knockdown
of Glp1r in our inducible Cre-loxP model. Based on significant
knockdown of Glp1r expression in islets and b cells and the
inability of GLP1R agonists in vitro and in vivo to stimulate insulin
release, there do not appear to be a sufficient number of b cell
Glp1r to mount functional responses in tamoxifen-treated
MIPcreER;Glp1r f/f animals. Moreover, the normal oral glucoseMetabolism 19, 1050–1057, June 3, 2014 ª2014 Elsevier Inc. 1053
Figure 3. Effects of GLP-1 Administration on Glucose Tolerance in MIPcreER;Glp1rf/f Mice
(A) Blood glucose (2.0 g/kg; 20%glucose) during IPGTT in tamoxifen- and vehicle-treatedMIPcreER;Glp1r f/fmice given i.p. saline or GLP-1 (10 mg) 15min prior to
glucose injection.
(B and C) AUC of glucose (B) and insulin concentrations at 15 min (C) from GTTs depicted in (A).
(D) Blood glucose (2.0 g/kg; 20% glucose) during IPGTT in tamoxifen- and vehicle-treated MIPcreER;Glp1r f/f given i.v. saline or GLP-1 (10 mg) 15 min prior to
glucose injection.
(E and F) AUC of glucose (E) and insulin concentrations at 15 min (F) from mice in (D).
(G) Blood glucose during IPGTT in mice with a heterozygous global Glp1r knockout (D/f: Tam), b cell-specific deletion of Glp1r (tamoxifen-treated
MIPcreER;Glp1r D/f; D/f: Veh), and a full complement of Glp1r (WT; Glp1 WT/f), with or without GLP-1 (10 mg, i.v.) given 15 min prior to glucose.
(H) AUC of glucose tolerance depicted in (G). Experiments used 8–12 mice per group; *p% 0.05; **p% 0.01; ***p% 0.001.
All data presented as mean ± SEM.
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b Cell-Specific Knockdown of Glp1rtolerance in this line is very reproducible, reducing the likelihood
that this is an underpowered observation.
The Action of Long-Acting GLP-1 Agonists, but Not
DPP-4i, Are Impaired with b Cell Knockdown of Glp1r
To address the mechanisms by which GLP-1 signaling contrib-
utes to diabetes therapeutics, we determined the impact of b
cell Glp1r knockdown on the response to GLP-1-based drugs.1054 Cell Metabolism 19, 1050–1057, June 3, 2014 ª2014 Elsevier InTamoxifen- and vehicle-treated MIPcreER;Glp1r f/f (Figures 4A
and 4B) and RIPcre;Glp1rf/f or WT (Figures S4) were given the
long-acting GLP1R agonist liraglutide 30 min prior to an i.p.
glucose load. The glucose profile after liraglutide was nearly
flattened in themice retaining b cellGlp1r. Treatment with liraglu-
tide improved glucose tolerance in mice with b cell Glp1r knock-
down, through either RIPcre or MIPcreER, but the effect was
blunted compared to the controls. Quite distinct from thec.
Figure 4. Effect of b Cell-Specific Knock-
down on Responses to GLP1R Agonist and
DPP-4i
(A) Blood glucose during IPGTT in tamoxifen- or
vehicle-treatedMIPcreER;Glp1rf/f (Tam, blue; Veh,
red) mice given liraglutide (200 mg/kg) or saline 4 hr
prior to glucose injection.
(B) AUC from GTT in (A).
(C) OGTT in tamoxifen- and vehicle-treated MIP-
creER;Glp1r f/f mice given i.p. vildagliptin (150 mg)
or saline (100 ml) 15 min before the glucose chal-
lenge.
(D) AUC from GTT in (C).
(E) Blood glucose during IPGTT in tamoxifen- and
vehicle-treated MIPcreER;Glp1r f/f mice given i.p.
saline or vildagliptin (150 mg) 30 min prior to
glucose injection.
(F) AUC from GTT in (E). Experiments used 8–16
mice per group, with *p% 0.05, **p% 0.01, ***p%
0.001.
All data presented as mean ± SEM. See Figure S4.
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b Cell-Specific Knockdown of Glp1rresponse to liraglutide, administration of the DPP-4i vildagliptin
lowered blood glucose equivalently in vehicle- and tamoxifen-
treated MIPcreER;Glp1r f/f mice challenged with either oral or
i.p. glucose (Figures 4C–4F). These findings indicate that liraglu-
tide exerts glucose-lowering actions, in part, through b cell
GLP1R. The intact glucose lowering by DPP-4 inhibition may
be explained by GLP-1 effects on non-b cell GLP1R populations
or may result from compensation by other factors that are also
DPP-4 substrates.
The results reported here indicate that glucose control
following oral administration of carbohydrate does not require
direct signaling through the b cell Glp1r in the mouse. A major
implication of these findings is that GLP-1 released into the cir-
culation after meals does not stimulate insulin secretion through
an endocrine mechanism. Rather our findings are compatible
with a model in which GLP-1 acts indirectly to mediate the incre-
tin effect, possibly through neural GLP1R. There is experimental
support for neural GLP1R in the hepatic portal vein to mediate
glucose tolerance (Ru¨ttimann et al., 2009; Vahl et al., 2007),
and recent evidence supports a similar mechanism in theCell Metabolism 19, 1050–10splanchnic bed to mediate the effects
of DPP-4 inhibitors (Waget et al., 2011).
Moreover, intracerebral administration
of GLP-1 transiently lowers blood
glucose in freely fed rats and reduces he-
patic glucose production (Barrera et al.,
2011b; Burmeister et al., 2012; Sandoval
et al., 2008). In this context, a strong case
can be made that neural GLP1R are the
extra-b cell receptors mediating glucose
lowering in the present study. That b cell
GLP1Rs are not necessary in the setting
of hyperglycemia induced by meals but
are needed for a normal response to
parenteral glucose administration may
be explained by redundancy and overlap
of insulinotropic signals initiated by
glucose ingestion and absorption.Our data indicate that b cell GLP1Rs are necessary for the
normal clearance of i.p. and i.v. glucose loads and for the insu-
linotropic response to exogenous GLP1R agonists. Whereas
these are experimental manipulations, a case can be made
that the results have both physiologic and pharmacologic rele-
vance. The relative responses of our knockdown and control
mice to i.p. and i.v. glucose is consistent with previous work
indicating that GLP-1 signaling is essential for b cells to main-
tain glucose competence or sensitivity to changes in ambient
glycemia (Flamez et al., 1998; Holz et al., 1993). This effect
has also been demonstrated in humans whereby Ex-9 reduces
glucose-stimulated insulin release during fasting when plasma
GLP-1 is low and unchanging (Salehi et al., 2010; Schirra
et al., 1998). Important in this context is recent work suggesting
that GLP-1 produced by a cells in the pancreatic islet is impor-
tant for local regulation of insulin secretion (Ellingsgaard et al.,
2011; Kilimnik et al., 2010; Nie et al., 2000). Our results are
compatible with this model of paracrine actions of a cell
GLP-1 on b cell GLP1R that enhance glucose-stimulated insulin
release.57, June 3, 2014 ª2014 Elsevier Inc. 1055
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b Cell-Specific Knockdown of Glp1rOn the basis of the studies reported here, we conclude that the
incretin role of GLP-1 cannot be explained by an endocrine
mechanism of action and that extraislet GLP1R pathways must
be invoked to explain theGLP-1 contribution to the incretin effect
(see Graphical Abstract). Direct signaling through GLP1R is
necessary for clearance or i.v. and i.p. glucose-induced hyper-
glycemia, possibly by promoting glucose competence, and it is
plausible that this is mediated by the actions of locally produced
GLP-1. However, the role of circulating GLP-1 acting on b cell
receptors is limited to circumstances where plasma GLP-1 is
substantially elevated, pharmacologically or otherwise, in a sus-
tained manner. These findings suggest distinct levels of b cell
regulation by GLP-1 with a component of direct, paracrine, or
neurocrine action and indirect mediation by extraislet GLP1R.
Moreover, our findings suggest that long-acting GLP1R agonists
co-opt the paracrine system and DPP-4 inhibitors act through
non-b cell GLP1R to exert their antidiabetic actions.
EXPERIMENTAL PROCEDURES
Reagents
GLP-1[7-36NH2] (21st Century Biochemicals), vildagliptin, liraglutide, exendin-
4 (Amylin) and Ex-9 (21st Century Biochemicals) were reconstituted in saline
containing 0.1% (w/v) bovine serum albumin, aliquotted and stored at 20C.
Liraglutide was kindly provided by Dr. Lotte Bjerre-Nielsen, Novo Nordisk.
Animal Husbandry and Glucose Tolerance Tests
Mice were housed in a temperature-controlled room under a 12 hr light-dark
cycle (lights on 0600–1800 hr) and fed standard chow with water available
ad libitum. Oral and i.p. GTTs, unless otherwise stated, were performed using
2.5 g/kg, 44% glucose and 2.5 g/kg, 25% glucose, respectively, by standard
methods; blood was sampled from the tail vein. Mixed nutrient oral GTT
(OGTT) was performed by training mice to consume 0.5ml of Ensure (see Sup-
plemental Experimental Procedures). All procedures were approved by the
Institutional Animal Care and Use Committee at the University of Cincinnati.
Transgenic Lines
The MIPcreER line generation has been previously described (Kaihara et al.,
2013; Wicksteed et al., 2010) with more characterization in the Supplemental
Information (see also Figure S2 and Figure S2 legend). The targeting strategy
and validation of the Glp1r f/f line and the global knockout (Glp1rCMVKO) is
described in Supplemental Experimental Procedures (see also Figure S1
legend). b cell-specific Glp1r knockdown Glp1rf/f mice were generated by
crossing with either RIPcre (Jackson Labs; Tg(Ins2-cre)25Mgn; stock number
003573) or MIPcreER lines as described in the Supplemental Experimental
Procedures. A secondary MIPcreER;Glp1r D/f mouse line was generated
following the breeding strategy of Feil (Feil et al., 2009; Supplemental Experi-
mental Procedures). The MIPcreER crosses were treated at approximately
2 months of age with 1 mg i.p. of tamoxifen (free base; Sigma; T5648) in
ethanol/sunflower oil (Feil et al., 2009) for 5 days, and experiments were
started 4 weeks later. Lack of response to i.v. GLP-1 during an IPGTT was
used to test for effective b cell knockdown.
Food Intake Studies
To test the anorectic effects of exendin-4 or liraglutide, animals were placed in
cages with fresh bedding and chow removed 4 hr before lights off. Mice were
injected i.p. at the beginning of the dark phase and food intake measured after
1, 2, 4, 6, and 24 hr. To assess chronic effects of liraglutide on body weight,
mice were given i.p. liraglutide (1.0 mg/kg; subcutaneously/day) for 14 days,
with food and body weight measured daily.
RNA Extraction and Real-Time PCR
For RNA extraction, samples were processed using an RNA mini kit (QIAGEN)
for whole tissues, the RNA aqueous mini kit (Ambion/Life Technologies) for
mouse islets, and the RNA aqueous micro kit (Ambion) for sorted cells. cDNAs1056 Cell Metabolism 19, 1050–1057, June 3, 2014 ª2014 Elsevier Inwere synthesized with SuperScript III First-Strand Synthesis kit (Invitrogen,
Life Technologies). PCR primers were: b-actin, 4352341E; Glp1r knockout
(KO), Mm00445292.m1; Glp1r intact, Mm0045290.m1; Gipr Mm01316344,
proglucagon, Mm00801712.m1; and Ins1, Mm01259683.m1. Messenger
RNA expression was calculated from the CT of target genes and b-actin using
standard methods.
Assays
The following assays were performed: insulin, ultrasensitive rat/mouse insulin
ELISA (Crystal Chem), GIP, EMD ELISA (Millipore), cAMP, acetylated version
of the cAMP ELISA kit (Cell Biolabs), and total GLP-1, ELISA (Meso Scale)
as previously described (Jessen et al., 2012).
Islet Cell Isolation, cAMP Stimulation, and FACS
Islets were isolated by standard procedures (Carter et al., 2009). For cAMP
experiments, 40 equally sized isletswere incubated inHEPESbalanced salt so-
lution (HBSS) and 0.1%bovine serumalbumin containing 3mMglucose for 1 hr
in 5% CO2 at 37
C and then in HBSS containing 15 mM glucose and 100 mM
isobutyl methylxanthine (IBMX), with or without 10 nM exendin-4, for 15 min.
Islets were lysed and cAMPmeasured. For fluorescence-activated cell sorting
(FACS) analysis, islets were dissociated by standard methods at the Research
Flow Cytometry Core at Cincinnati Children’s Hospital (Jayaraman, 2011).
Statistical Analysis
Data are presented as mean ± SEM. Analyses were performed using
GraphPad Prism, version 5.01 (GraphPad Software). Comparisons of two
samples were done with unpaired two-tailed t tests. Analysis of multiple
groups used one-way ANOVA with a multiple comparison test, and two-way
ANOVA was used to compare different treatments in two mouse strains.
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